Longboard Pharmaceuticals Inc. (LBPH) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Longboard Pharmaceuticals... (LBPH)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

59.98

0.00 (0.00%)

At close: Nov 29, 2024, 6:00 PM

undefined% (undefined)

Bid	n/a
Market Cap	2.34B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.25
PE Ratio (ttm)	-26.66
Forward PE	n/a
Analyst	Hold

Ask	n/a
Volume	655,798
Avg. Volume (20D)	1,724,505
Open	59.98
Previous Close	59.98
Day's Range	59.98 - 59.98
52-Week Range	3.82 - 60.03
Beta	undefined

About LBPH

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurolog...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 12, 2021

Employees 50

Stock Exchange NASDAQ

Ticker Symbol LBPH

Website https://www.longboardpharma.com

Analyst Forecast

According to 9 analyst ratings, the average rating for LBPH stock is "Hold." The 12-month stock price forecast is $60, which is an increase of 0.03% from the latest price.

Buy 55.56%

Hold 33.33%

Sell 0.00%

Stock Forecasts

News

2 months ago · businesswire.com

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Longboard Pharma...

3 months ago · zacks.com

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%

LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.

3 months ago · benzinga.com

Dow Surges Over 200 Points; Longboard Pharmaceuticals Shares Jump

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.8% on Monday.

3 months ago · invezz.com

S&P 500 hits record high; Dow gains as Longboard Pharmaceuticals surges 51% and tech stocks rise

The S&P 500 rose to a new record high of 5,859 on Monday ahead of key corporate earnings later this week. At the time of writing, the S&P 500 index was 0.8% higher than the previous close.

3 months ago · marketwatch.com

Longboard Pharmaceuticals' stock soars amid Lundbeck's $2.6 billion deal to acquire the company

H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

3 months ago · barrons.com

Longboard Pharmaceutical Stock Soars 51%. It's Being Bought for $2.6 Billion.

Longboard shareholders will be offered $60 per share in cash.

3 months ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Longboard (NASDAQ: LBPH) for possible breaches of fiduciary duty and other violations of law in its transaction with Lundbeck. Click here to lear...

3 months ago · businesswire.com

LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) to H. Lundbeck A/S for $60.00 per share in...

3 months ago · businesswire.com

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

VALBY, Denmark & LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbe...

3 months ago · gurufocus.com

Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussion of Topline Phase 1 SAD Data

Q2 2024 Longboard Pharmaceuticals Inc Earnings Call and Discussi {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"GuruFocus.com","it...

3 months ago · businesswire.com

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

3 months ago · businesswire.com

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

3 months ago · zacks.com

Longboard Stock Soars on FDA Designations for Epilepsy Drug

The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.

4 months ago · businesswire.com

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024

5 months ago · seekingalpha.com

Longboard Pharmaceuticals, Inc. (LBPH) Q2 2024 Earnings Call Transcript

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q2 2024 Earnings Call Transcript August 1, 2024 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kev...

If you are looking for stocks that are well positioned to maintain their recent uptrend, Longboard Pharmaceuticals (LBPH) could be a great choice. It is one of the several stocks that passed through o...

5 months ago · fool.com

3 Russell 2000 Growth Stocks That Could Be Worth the Risk

Interest rate cuts may could provide a major catalyst for Russell 2000 listed stocks. These three Russell 2000 constituents warrant a serious look by growth investors right now.

6 months ago · zacks.com

Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet

The mean of analysts' price targets for Longboard Pharmaceuticals (LBPH) points to a 43.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...

Load More News

AI Score

Unlock

AI Score

AI Score

Unlock

AI Score

About LBPH

Analyst Forecast

2 months ago · businesswire.com

3 months ago · zacks.com

3 months ago · benzinga.com

3 months ago · invezz.com

3 months ago · marketwatch.com

3 months ago · barrons.com

3 months ago · businesswire.com

3 months ago · businesswire.com

3 months ago · businesswire.com

3 months ago · gurufocus.com

3 months ago · businesswire.com

3 months ago · businesswire.com

3 months ago · zacks.com

4 months ago · businesswire.com

5 months ago · seekingalpha.com

5 months ago · businesswire.com

5 months ago · businesswire.com

5 months ago · zacks.com

5 months ago · fool.com

6 months ago · zacks.com